EGFR and head and neck squamous cell carcinoma: The EGFR signaling pathway contributed to the development and progression of HNSCC, and the EGFR-targeted drug erlotinib had shown good efficacy in the treatment of HNSCC (Gross et al. 2014; Stanam et al. 2015; Allen et al. 2015; Xu et al. 2017).